HK Stock Movement | HBM Holdings-B (02142) Rises Over 6% in Early Trading as Subsidiary Nona Biotechnology Signs Non-Exclusive License Agreement with Pfizer

Stock News

Nov 20

HBM Holdings-B (02142) surged more than 6% in early trading, reaching HK$14.68 with a turnover of HK$8.02 million by the time of reporting. The uptick follows an announcement on November 19 that its wholly-owned subsidiary, Nona Biotechnology (Suzhou) Co., Ltd. (Nona Biotechnology), has entered into a non-exclusive license agreement with Pfizer to advance preclinical antibody discovery for multiple potential disease indications. Under the agreement, Pfizer gains global access to Nona Biotechnology's proprietary HCAb platform for developing fully human heavy-chain-only antibodies. Nona Biotechnology will receive an upfront payment and is eligible for regulatory, clinical, and commercial milestone payments. Additionally, Nona Biotechnology may collaborate with Pfizer to leverage its HCAb platform, advanced B-cell screening technology, and integrated services for antibody discovery, development, and engineering.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1108344579"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108344579\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1108344579?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 09:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108344579","market":"us","top_or_hot":-1,"title":"HK Stock Movement | HBM Holdings-B (02142) Rises Over 6% in Early Trading as Subsidiary Nona Biotechnology Signs Non-Exclusive License Agreement with Pfizer","media":"Stock News","content":"<p>HBM Holdings-B (02142) surged more than 6% in early trading, reaching HK$14.68 with a turnover of HK$8.02 million by the time of reporting. The uptick follows an announcement on November 19 that its wholly-owned subsidiary, Nona Biotechnology (Suzhou) Co., Ltd. (Nona Biotechnology), has entered into a non-exclusive license agreement with Pfizer to advance preclinical antibody discovery for multiple potential disease indications. Under the agreement, Pfizer gains global access to Nona Biotechnology's proprietary HCAb platform for developing fully human heavy-chain-only antibodies. Nona Biotechnology will receive an upfront payment and is eligible for regulatory, clinical, and commercial milestone payments. Additionally, Nona Biotechnology may collaborate with Pfizer to leverage its HCAb platform, advanced B-cell screening technology, and integrated services for antibody discovery, development, and engineering.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | HBM Holdings-B (02142) Rises Over 6% in Early Trading as Subsidiary Nona Biotechnology Signs Non-Exclusive License Agreement with Pfizer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | HBM Holdings-B (02142) Rises Over 6% in Early Trading as Subsidiary Nona Biotechnology Signs Non-Exclusive License Agreement with Pfizer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-20 09:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HBM Holdings-B (02142) surged more than 6% in early trading, reaching HK$14.68 with a turnover of HK$8.02 million by the time of reporting. The uptick follows an announcement on November 19 that its wholly-owned subsidiary, Nona Biotechnology (Suzhou) Co., Ltd. (Nona Biotechnology), has entered into a non-exclusive license agreement with Pfizer to advance preclinical antibody discovery for multiple potential disease indications. Under the agreement, Pfizer gains global access to Nona Biotechnology's proprietary HCAb platform for developing fully human heavy-chain-only antibodies. Nona Biotechnology will receive an upfront payment and is eligible for regulatory, clinical, and commercial milestone payments. Additionally, Nona Biotechnology may collaborate with Pfizer to leverage its HCAb platform, advanced B-cell screening technology, and integrated services for antibody discovery, development, and engineering.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0289739699.SGD","symbol_name":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","start_time":0,"source_url":"","article_id":"1108344579","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108344579","pubTimestamp":1763602697,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HBM Holdings-B (02142) surged more than 6% in early trading, reaching HK$14.68 with a turnover of HK$8.02 million by the time of reporting. The uptick follows an announcement on November 19 that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","PFE":"辉瑞","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4007":"制药","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK1161":"生物科技","SG9999002232.USD":"Allianz Global High Payout USD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","BK4581":"高盛持仓","BK4599":"减肥药","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","SG9999002224.SGD":"Allianz Global High Payout SGD","02142":"和铂医药-B","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK1574":"生物医药B类股","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK1583":"高瓴概念","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4592":"伊斯兰概念","LU0058720904.USD":"联博国际健康护理基金A","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4588":"碎股","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","SG9999001176.USD":"United Global Healthcare Acc USD"},"translate_title":"港股动向|HBM Holdings-B(02142)早盘涨超6%子公司诺娜生物与辉瑞签署非独家许可协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":1,"PFE":1},"content_text":"HBM Holdings-B (02142) surged more than 6% in early trading, reaching HK$14.68 with a turnover of HK$8.02 million by the time of reporting. The uptick follows an announcement on November 19 that its wholly-owned subsidiary, Nona Biotechnology (Suzhou) Co., Ltd. (Nona Biotechnology), has entered into a non-exclusive license agreement with Pfizer to advance preclinical antibody discovery for multiple potential disease indications. Under the agreement, Pfizer gains global access to Nona Biotechnology's proprietary HCAb platform for developing fully human heavy-chain-only antibodies. Nona Biotechnology will receive an upfront payment and is eligible for regulatory, clinical, and commercial milestone payments. Additionally, Nona Biotechnology may collaborate with Pfizer to leverage its HCAb platform, advanced B-cell screening technology, and integrated services for antibody discovery, development, and engineering.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}